REMARKS

First, Applicants wish to thank Examiners Zhou for his time and helpful suggestions during his interview with Applicant's representative, Cheryl H. Agris on November 28, 2006. During the interview, the structure of the Appeal Brief and further possible amendments were discussed. Additionally, there was a discussion regarding which rejections are still pending. The Examiner has issued an Advisory Action dated June 8, 2006. Applicants below respond to issues raised in the Advisory Action.

1. The Rejection of Claims 1-2, 4 8 12-14, 19 and 42-50 Under 35 USC §102(b)

Claims 1-2, 4, 8, 12-14, 19 and 42-50 have been rejected under 35 U.S.C. §102(b) as being anticipated by Miller et al. It is asserted that the product disclosed by Miller et al. is the same as the claimed product since the Miller et al. product would act as an RNase H substrate when complexed with a complementary RNA.

in order to advance prosecution, claims 1-2, 4, 8, 12-14, 19 and 42-43, 45-48 and 50 were canceled in the Amendment Under 37 CFR §1.116 submitted on February 14, 2006. Applicants have in the instant amendment and response have canceled claims 44 and 49.

In view of the cancellation of claims 44 and 49, Applicants assert that the rejection under 35 U.S.C. §102(b) has been overcome. Therefore, Applicants respectfully request that the rejection be withdrawn.

2. Conclusion

Appellants assert that these claim amendments put the claims in condition for allowance.

Brakel et al. Serial No. 08/479,999 Filed: December 8, 2006 Page 5 [Amendment Under 37 C.F.R. §1.116]

If a telephone conversation would further the prosecution fo the present application, Applicants' undersigned attorney request that he be contacted at the number provided below.

Dated: 17/8/06

Cheryl H. Agris, Reg. No. 34,086

Attorney for Appellants (914) 712-0093

Respectfully submitted,

ENZO THERAPUTICS, INC C/o ENZO BIOCHEM., INC. 527 Madison Avenue, 9th Floor New York, New York 10022